May 8, 2013

There is as much as $10 billion in branded pharmaceutical sales that could make the switch from prescription-only to over-the counter in the next five years, suggested Joseph Papa, Perrigo chairman, CEO and president, to analysts on Tuesday.

March 18, 2013

Perrigo announced that it has begun shipments of guaifenesin 600-mg extended-release tablets. It's the first product that is generically equivalent to Reckitt Benckiser's Mucinex 600-mg extended-release tablets.

February 1, 2013

Leading private-label supplier Perrigo has acquired pet health company Velcera for $160 million.

January 22, 2013

Perrigo announced that it has begun shipments of over-the-counter nicotine polacrilex mini lozenge USP, 2 mg (mint flavor) and 4 mg (mint flavor), comparable to GlaxoSmithKline's Nicorette mini lozenge.

November 8, 2012

Business for OTC store brands is expected to boom in the coming year, Perrigo chairman and CEO Joseph Papa told analysts discussing the private-label manufacturer's first quarter results during a conference call Wednesday, even as the growth rate across the entire OTC category slows.

October 10, 2012

Perrigo on Wednesday announced that it has received approval from the Food and Drug Administration for its abbreviated new drug applications to market over-the-counter nicotine polacrilex mini lozenge USP in both 2-mg and 4-mg strengths.

September 13, 2012

An expanded offering of private-label pet care products will come soon to retailers' shelves, following the acquisition of Sergeant's Pet Care Products by Perrigo, the leading global provider of store-brand health and personal care items.

February 17, 2012

Clarinex (desloratadine), the next-generation prescription allergy remedy to the second-generation Claritin, is 1-of-3 blockbuster prescription medicines that may make the crossover from prescription-only to over-the-counter in the near future.

June 30, 2011

Perrigo on Wednesday announced that its closing date to complete the acquisition of Paddock Labs — a generic pharmaceutical and specialty over-the-counter products manufacturer — has been delayed by an extended Federal Trade Commission review.